{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-070280","form_type":"8-K","ticker":"FATE","cik":"0001434316","company_name":"FATE THERAPEUTICS INC","filed_at":"2025-05-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.282735+00:00","generated_at":"2026-05-21T14:32:44.813877+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Fate Therapeutics Q1 cash $272.7M; FT819 gets RMAT designation for SLE","bullets":["Cash, equivalents, and investments $272.7M as of March 31, 2025; projected runway through 1H27.","FT819 granted RMAT designation by FDA for moderate-to-severe SLE; new data at EULAR June 11.","Phase 1 study expanded to include AAV, IIM, SSc autoimmune disease cohorts; enrollment ongoing.","Revenue $1.6M from Ono collaboration; total operating expenses $42.9M (R&D $29.1M, G&A $13.8M).","Common shares outstanding 114.6M; preferred shares (convertible 5:1) 2.8M; pre-funded warrants 3.9M."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-070280","json":"https://secwatch.observer/filing/0000950170-25-070280.json","markdown":"https://secwatch.observer/filing/0000950170-25-070280.md","text":"https://secwatch.observer/filing/0000950170-25-070280.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1434316/000095017025070280/0000950170-25-070280-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1434316/000095017025070280/fate-20250513.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T14:32:44.813877+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}